KR20010108063A - 단백질 인산화 효소의 조절 및 암의 화학적 치료를 위한3-헤테로아릴리데닐-2-인돌리논 화합물 - Google Patents

단백질 인산화 효소의 조절 및 암의 화학적 치료를 위한3-헤테로아릴리데닐-2-인돌리논 화합물 Download PDF

Info

Publication number
KR20010108063A
KR20010108063A KR1020017008453A KR20017008453A KR20010108063A KR 20010108063 A KR20010108063 A KR 20010108063A KR 1020017008453 A KR1020017008453 A KR 1020017008453A KR 20017008453 A KR20017008453 A KR 20017008453A KR 20010108063 A KR20010108063 A KR 20010108063A
Authority
KR
South Korea
Prior art keywords
cancer
well
compound
solution
indolinone
Prior art date
Application number
KR1020017008453A
Other languages
English (en)
Korean (ko)
Inventor
펭조 탕
선리
라우라카이 샤우버
피터제이 란젝커
Original Assignee
수젠, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 수젠, 인크. filed Critical 수젠, 인크.
Publication of KR20010108063A publication Critical patent/KR20010108063A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
KR1020017008453A 1998-12-31 1999-12-30 단백질 인산화 효소의 조절 및 암의 화학적 치료를 위한3-헤테로아릴리데닐-2-인돌리논 화합물 KR20010108063A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11431398P 1998-12-31 1998-12-31
US60/114,313 1998-12-31
PCT/US1999/031232 WO2000038519A1 (en) 1998-12-31 1999-12-30 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy

Publications (1)

Publication Number Publication Date
KR20010108063A true KR20010108063A (ko) 2001-12-07

Family

ID=22354480

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017008453A KR20010108063A (ko) 1998-12-31 1999-12-30 단백질 인산화 효소의 조절 및 암의 화학적 치료를 위한3-헤테로아릴리데닐-2-인돌리논 화합물

Country Status (10)

Country Link
EP (1) EP1139754A4 (ja)
JP (1) JP2002533360A (ja)
KR (1) KR20010108063A (ja)
CN (1) CN1356872A (ja)
AU (1) AU760964B2 (ja)
BR (1) BR9916735A (ja)
CA (1) CA2357042A1 (ja)
IL (1) IL143920A0 (ja)
MX (1) MXPA01006742A (ja)
WO (1) WO2000038519A1 (ja)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
PT1233943E (pt) * 1999-11-24 2011-09-01 Sugen Inc Formulações para agentes farmacêuticos ionizáveis como ácidos livres ou bases livres
BRPI0108394B8 (pt) * 2000-02-15 2021-05-25 Upjohn Co inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos
PL363110A1 (en) * 2000-02-28 2004-11-15 Aventis Pharma S.A. A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
MY128450A (en) 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
JP2003535847A (ja) 2000-06-02 2003-12-02 スージェン・インコーポレーテッド 蛋白質キナーゼ／ホスファターゼ阻害剤としてのインドリノン誘導体
CA2440555A1 (en) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
WO2002096361A2 (en) 2001-05-30 2002-12-05 Sugen, Inc. 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
AR038957A1 (es) * 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
WO2003035616A2 (en) * 2001-10-25 2003-05-01 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2002348393A1 (en) * 2001-10-25 2003-05-06 Merck And Co., Inc. Tyrosine kinase inhibitors
WO2003035619A1 (en) * 2001-10-25 2003-05-01 Merck & Co., Inc. Tyrosine kinase inhibitors
US7109185B2 (en) * 2001-11-21 2006-09-19 Sugen, Inc. Pharmaceutical formulations comprising indolinone derivatives
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
AU2002360753B2 (en) 2001-12-27 2008-08-21 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
RU2005101624A (ru) 2002-06-25 2005-06-27 Уайт (Us) Применение производных тиооксиндола в терапии кожных нарушений
IL165395A0 (en) * 2002-06-25 2006-01-15 Wyeth Corp Use of thio-oxubdile derivatives in treatment of hormone-related conditions
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
EP1525200B1 (en) 2002-08-02 2007-10-10 AB Science 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
BR0316238A (pt) * 2002-11-15 2005-10-11 Warner Lambert Co Quimioterapia de associação compreendendo um inibidor de mek e capecitabina para tratamento de câncer
AU2004283162B2 (en) 2003-10-23 2011-12-15 Ab Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
CN100432071C (zh) * 2004-11-05 2008-11-12 中国科学院上海药物研究所 取代1h－吲哚－2－酮类化合物及其制备方法和用途
EP1874305B1 (en) 2005-04-04 2014-08-27 AB Science Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
US8246966B2 (en) 2006-08-07 2012-08-21 University Of Georgia Research Foundation, Inc. Trypanosome microsome system and uses thereof
EP2088863A2 (en) 2006-11-22 2009-08-19 University Of Georgia Research Foundation, Inc. Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents
PL2780011T3 (pl) 2011-11-11 2018-08-31 Eli Lilly And Company Terapia skojarzona raka jajnika
CN107517589A (zh) 2015-01-08 2017-12-26 小利兰·斯坦福大学托管委员会 提供骨、骨髓及软骨的诱导的因子和细胞
SI3288940T1 (sl) 2015-04-29 2021-07-30 Janssen Pharmaceutica Nv Azabenzimidazoli in njihova uporaba kot modulatorji AMPA-receptorja
CN105585558A (zh) * 2015-12-15 2016-05-18 贵州大学 双烷氧基嘧啶拼接3-烯键氧化吲哚衍生物及其制备方法及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
ES2251741T3 (es) * 1996-08-23 2006-05-01 Sugen, Inc. Bibliotecas combinatorias de indolinona y productos afines y metodos para el tratamiento de enfermedades.

Also Published As

Publication number Publication date
AU2221500A (en) 2000-07-31
EP1139754A4 (en) 2002-12-18
IL143920A0 (en) 2002-04-21
CA2357042A1 (en) 2000-07-06
JP2002533360A (ja) 2002-10-08
AU760964B2 (en) 2003-05-22
EP1139754A1 (en) 2001-10-10
MXPA01006742A (es) 2004-04-21
BR9916735A (pt) 2001-09-25
CN1356872A (zh) 2002-07-03
WO2000038519A1 (en) 2000-07-06

Similar Documents

Publication Publication Date Title
KR20010108063A (ko) 단백질 인산화 효소의 조절 및 암의 화학적 치료를 위한3-헤테로아릴리데닐-2-인돌리논 화합물
KR100743287B1 (ko) 피롤기로 치환된 2-인돌리논 단백질 인산화 효소 억제제
US7189721B2 (en) Bicyclic protein kinase inhibitors
US6329375B1 (en) Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
US6525072B1 (en) Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
US6316635B1 (en) 2-indolinone derivatives as modulators of protein kinase activity
EP1259234B9 (en) 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
US6696448B2 (en) 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
US6849641B1 (en) Azaindole tyrosine kinase inhibitors
US6569868B2 (en) 2-indolinone derivatives as modulators of protein kinase activity
US20030191162A1 (en) 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
US20030073837A1 (en) 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
MXPA00011770A (en) Pyrrole substituted 2-indolinone protein kinase inhibitors

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid